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Abstract  
 
Self-harm, such as self-cutting, self-poisoning or jumping from height, regardless of intentions, 
is common among people with schizophrenia. We wished to investigate brain activations relating 
to self-harm, in order to test whether these activations could differentiate between schizophrenia 
patients with self-harm and those without. We used event-related functional MRI with a go/no-
go response inhibition paradigm. Fourteen schizophrenia patients, with a history of self-harm, 
were compared with 14 schizophrenia patients without a history of self-harm and 17 healthy 
control participants. In addition, we used standard clinical measures and neuropsychological tests 
to assess risk factors associated with self-harm. The right dorsolateral prefrontal cortex (DLPFC) 
and the left posterior cingulate cortex differentiated all three groups; brain activation in these 
regions being greatest in the control group, and the self-harm patient group being greater than in 
the non -self-harm patient group. In the self-harm patient group, right DLPFC activity was 
positively correlated with severity of suicidal thinking. In addition, both patient groups showed 
less activation in the right orbitofrontal cortex, left ventral anterior cingulate cortex and right 
thalamus. This is the first study to report right DLPFC activation in association with self-harm 
and suicidal thinking in patients with schizophrenia. This area could be a target for future 
neuromodulation studies to treat suicidal thinking and self-harm behaviors in patients with 
schizophrenia.   
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1. Introduction 
 
Self-harm is a significant risk factor for later completed suicide: previous self-harm carries an 
eight-fold increase for completed suicide ofin patients with schizophrenia (Hor and Taylor, 
2010). 
(Hor and Taylor, 2010)(Hor and Taylor, 2010)(Hor and Taylor, 2010)(Hor and Taylor, 
2010)Systematic reviews have indicated that clinical features associated with suicide in patients 
with schizophrenia include depressive episodes, previous suicide attempts, and substance abuse 
(Hawton et al. , 2005, Hor and Taylor, 2010). Other risk factors associated with suicide attempts 
included high impulsivity, relatively preserved executive cognitive functions, and good insight 
into their illness (Kim et al. , 2003). Iancu and colleagues have highlighted the importance of 
impulsivity associated with suicide attempts and ideation in patients with schizophrenia (Iancu et 
al. , 2010). They showed that a high implusivity group, compared with a low implusivity group, 
had higher scores on suicide ideation scores and more lifetime suicide attempts. High impulsivity 
is particularly linked to schizophrenia patients who have clinical histories involving both suicide 
attempts and non-suicidal self-harming acts (Mork et al. , 2013). In our recent study, we 
identified impulsivity as one of five significant factors that differentiated schizophrenia patients 
with self-harm from those without (Pluck et al. , 2012).     
 
Although the prefrontal cortex has been implicated in self-harm in depression, the neural basis of 
mental processes associated with suicide risk in patients with schizophrenia is not well studied. 
Neuroimaging studies have revealed reduced glucose metabolism in the prefrontal cortex in 
depressive patients with high-lethality suicide attempts compared to those with low-lethality 
attempts (Oquendo et al. , 2003). Depression patients who completed suicide, compared with 
non-suicidal depression patients, had significantly higher regional cereberal blood flow (rCBF) 
in the right hemisphere (Amen et al. , 2009). Consistent with this, Hunter and colleagues 
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reported increased right prefrontal EEG coherence when patients with depression experienced 
worsening of suicidal ideation and mood symptoms during anti-depressant treatment (Hunter et 
al. , 2010). Further, in patients with depression, high levels of mental pain associated with 
suicide were related to increased rCBF in the right dorsolateral prefrontal cortex (van Heeringen 
et al. , 2010). These activations are generally consistent with observations that schizophrenia 
patients who attempt suicide have better prefrontal neurocognitive functions than those that do 
not (Nangle et al. , 2006). An exception to this is that they also display higher levels of 
impulsivity (Pluck, Lekka, 2012), a feature linked to right, particularly inferior, prefrontal cortex 
function(Aron et al. , 2014).  
 
One of the main neuropsychological measures of response inhibition and impulsivity is the 
go/no-go procedure. In this task participants are asked to press a button when they see letters 
flashed onto a screen. Responses to these letters become pre-potent for the go trials. However 
they are asked to inhibit this reponse and to avoid pressing the button for a particular letter (the 
no-go trials). Impulsivity is manifest as an inability to withhold the button press for the µQRJR¶ 
letter. In a functional MRI go/no-go study using a healthy sample, Horn and colleagues found a 
SRVLWLYHDVVRFLDWLRQEHWZHHQVFRUHVRQ(\VHQFN¶VLPSXOVLYLW\VFDOHDQGULJKWventrolateral 
prefrontal cortex activation (%URGPDQQ¶VDUHD44/45) (Horn et al. , 2003). Kaladjian and 
colleagues found a positive corelation between scores on the Barratt Impulsiveness Scale and 
brain activation in the right ventrolateral prefrontal cortex (BA 44/45/47) in patients with 
schizophrenia (Kaladjian et al. , 2011). However to date, no studies have examined neural 
activity in self-harm schizophrenia patients during performance of the go/no-go task.  
 
The aim of the current study was to investigate the neurophysiological substrate of go/no-go 
response inhibition associated with self-harm in people with schizophrenia. We hypothesized 
that: 1) patients with schizophrenia, when compared with controls, would show less prefrontal 
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activity during task performance, and 2) patients with a history of self-harm would show greater 
prefrontal activation than those without a history of self-harm. We were particularly interested in 
LQYHVWLJDWLQJZKHWKHUEUDLQDFWLYDWLRQVLQµVHOI-KDUPVSHFLILF¶DUHDVZHUHFRUUHODWHGZLWKFOLQLFDO
scales for self-harm and suicide in patients with history of self-harm. By including a sample of 
healthy controls, we hoped to differentiate self-harm specific brain areas from schizophrenia 
specific brain areas during the same task.  
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2. METHODS 
 
2.1 Participants 
 
Fourteen schizophrenia patients with history of self-harm, fourteen patients without history of 
self-harm, and 17 healthy controls participated. A standard definition was used to allocate 
patients to either the self-harm or no self-harm group, based on any past self-initiated acts (such 
as self-cutting, poisoning or jumping from a height) intended to cause self-harm (Hawton et al. , 
2002). The information for the classification was acquired during a clinical interview and case 
notes review using standard measures to record details of the acts (Gratz, 2001, Swann et al. , 
2005). Demographic and clinical variables for each group and any between-group differences are 
listed in Table 1. After fully describing the study to the participants, written informed consent 
was obtained. The study had Research Ethics Committee approval.  
 
2.2 Clinical and cognitive assessments  
 
During a clinical interview with a psychiatrist, the frequency of acts of self-harm were recorded 
using the Deliberate Self-Harm Inventory (DSHI), a schedule that records instances of a range of 
common self-harm behaviors (Gratz, 2001). Other psychological features were measured with 
the Barratt Impulsiveness Scale-11 (BIS-11) (Patton et al. , 1995), and the Beck Hopelessness 
Scale (BHS) (Beck and Steer, 1993). Patients were assessed with the InterSePT Scale for 
Suicidal Thinking (ISST), a 12-item instrument for the assessment of current suicidal ideation in 
patients with schizophrenia and schizoaffective disorders (Lindenmayer et al. , 2003), the 
Calgary Depression Scale (Addington et al. , 1990); the Schedule for the Assessment of Insight 
(David, 1990), and social functioning was assessed with the Life Skills Profile (Rosen et al. , 
1989). Finally, schizophrenia symptoms were rated using the Schedules for the Assessment of 
Positive and Negative Symptoms(Andreasen, 1983, 1984). 
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All participants were also interviewed by a neuropsychologist. Premorbid IQ was estimated with 
the National Adult Reading Test (Corrigan and Nelson, 1998), and current IQ with the Wechsler 
Abbreviated Scale of Intelligence (Wechsler, 1999). Sustained attention was measured using a 
computerized continuous performance test (CPT) (Birkett et al. , 2007), and frontal executive 
function with the Trail Making Test (Reitan, 1958).  
 
2.3 fMRI task, data acquisition and analysis 
 
In an event-related fMRI design, all participants completed two functional MR runs (each run 
lasting 840s, acquiring data at 420 time-points), incorporating 71 go trials, 71 no-go trials and 68 
resting trials in an equi-probable go and no-go task. Each trial consisted of an event inof 8s: the 
presentation of each trial started with a descending series of numbers to build-up preparedness to 
UHVSRQG³´IRUPVIROORZHGE\PVEODQNVFUHHQ³´IRUPVIROORZHG by 750ms 
EODQNVFUHHQ«7KHQHLWKHUDµJR¶VLJQDO³;´RUDµQR-JR¶VLJQDO³$´ZDVSUHVHQWHGIRUPV
followed by an additional 2750ms black screen for responding. This equi-probable go/no-go task 
HQDEOHVWKHQXPEHURIµJR¶DQGµno-JR¶WULDOVto be constant, so that brain activity associated with 
novelty (rare target events) can be controlled for (Liddle et al. , 2001). Trial order was optimized 
for statistical power and psychological validity using a genetic algorithm (Wager and Nichols, 
2003). All participants had a practice session immediately before fMRI.   
 
Functional imaging datasets were acquired using a 3T scanner (Achieva 3.0T, Philips 
Healthcare, Best, The Netherlands) at the University of Sheffield. A single-shot, gradient  
recalled,  echo-planar  technique  was  used  to  acquire  22x6mm  thick contiguous transverse  
slices  at  420  time  points per run (TR=2000ms,  TE=35 ms,  SENSE factor=1.5, in-plane  
resolution 1.8x1.8 mm). A high resolution T1-weighted structural MRI was also acquired for 
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each participant using a 3D MPRAGE sequence (TR=15ms; TE=4.4ms; 0.8×0.8×0.8mm voxel 
size). Data were analyzed using statistical parametric mapping (SPM8, 
http://www.fil.ion.ucl.ac.uk/spm). Pre-processing involved re-alignment, unwarping, co-
registration of the mean functional image with the structural scan of each participant, spatial 
normalization, and spatial smoothing using a Gaussian kernel of full-width half-maximum 6mm.  
  
In the first level of analysis for individual participants, we used only correct no-go and go trials, 
to create statistical parametric maps for no-go minus rest, go minus rest, no-go minus go and go 
minus no-go trials. For the second-level group statistics, within-group t-tests were performed 
using the random-effects approach with a significance threshold of p<.05, corrected for family-
wise error-rate, with a cluster extent threshold of 5 voxels. We further performed a whole-brain 
analysis of variance (ANOVA) for all three groups. Significant clusters associated with the main 
effect of group were identified using a height threshold of p<.001 (uncorrected for multiple 
comparisons) and a cluster extent threshold of 5 voxels. Anatomical localizations were 
transformed into the stereotactic space of Talairach and Tournoux. The mean activation in each 
of the clusters for each participant was extracted using the MarsBaR toolbox 
(http://marsbar.sourceforge.net/). These data were then used to conduct between-group and 
correlation analyses using SPSS (Version 17, SPSS Inc, Chicago).  
 
All correlation analyses of brain activation with task performance, clinical and cognitive 
measures were conducted with a threshold of p=.0083 (i.e., .05 divided 6, the number of regions 
of interest, see results section) and, accordingly, adjusted p-values are reported hereafter. All 
correlation analyses were initially conducted in each group separately, in order to avoid the 
possibility that group differences might have an impact on the correlations. The same correlation 
analyses were then later conducted with all participants.  
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3. RESULTS 
 
3.1 Behavioral performance during fMRI 
 
Behavioral data during scanning showed that all groups performed with comparable high 
accuracy (self-harm patient group: 94.6%, SD=7.4; non self-harm patient group: 96.1%, SD=4.4; 
control group: 97.2%, SD=4.6). There were no significant between-group differences in the 
number of total correct responses, commission or, omission errors. Likewise, the mean reaction 
time (RT) for go trials was not significantly different across groups (self-harm patient group: 
433.6ms, SD=110.9; non self-harm patient group: 399.8, SD=105.2; control group: 355.8ms, 
SD=93.8) [F(2, 42)=2.23; p=.12]. However, RT variability was significantly different between 
groups [F(2, 42)=3.76; p<.05], with the self-harm patient group exhibiting a significant increase 
of RT variability compared with the control group in a post-hoc pair-wise comparison (p<.01). 
 
3.2 fMRI findings 
 
As shown in Table 2, the no-go versus rest contrast showed anterior cingulate cortex activation 
across all groups. The control group activated right ventrolateral prefrontal cortex (VLPFC, BA 
47), which was absent in the patient groups. Conversely, precuneus/posterior cingulate activation 
(BA 7) was seen in the patient groups, but not in the control group. The no-go versus go contrast 
did not show any significant brain areas in any groups. The go versus rest contrast in all 
participant groups showed activations in left motor and sensory cortices, anterior 
cingulate/medial prefrontal cortex, and right cerebellum (Supplementary Table 1). In the go 
versus no-go contrast, control participants activated left pre and postcentral gyri, and right 
cerebellum (lobule V). For the same contrast in patient groups, motor and sensory cortical areas, 
and the cerebellum were activated as in the control group, with the additional recruitment of the 
basal ganglia and insula (Supplementary Table 2). 
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A three-group ANOVA for the no-go versus rest contrast showed a significant main effect of 
group in the right VLPFC (BA 47) [F(2, 42)=11.12; p < .001] , the right DLPFC (BA 9) [F(2, 
42)=10.89; p < .001], the ventral anterior cingulate cortex (ventral ACC; BA 24) [F(2, 
42)=10.76; p < .001] , the PCC (two foci: BA 23, F(2, 42)=9.08; p < .01, and BA 31, F(2, 
42)=11.10; p < .001,) and the thalamus [F(2, 42)=10.67; p < .001]. Between-group pair-wise 
comparisons revealed three distinct patterns (see Table 3). First, compared with the two patient 
groups, the control group showed increased activation in the right VLPFC (BA 47), ventral ACC 
(BA 24) and right thalamus: no difference was found between the two patient groups. Second, in 
the right dorsal PCC (BA 31), the control group showed significantly less activation, compared 
with the patient groups. Hence the above two networks were sensitive to diagnosis (i.e., 
schizophrenia versus control). Finally, activations in the right DLPFC (BA 9) and the left PCC 
(BA 23) differentiated all three groups (activation in the control group > self-harm patient group 
> non self-harm patient group; See Table 3). Hence, activities in these areas were sensitive to 
self-harm as well as the diagnosis of schizophrenia.     
 
In terms of task performance (corrected threshold of p=0.0083), activity in the ventral ACC (BA 
24) was significantly negatively correlated with the number of omission errors during scanning 
(r=-.584, p=.046) in the self-harm patient group. The same correlation was significant when all 
participants were combined (r=-.419, p=.024). In addition, activity in both the same ventral ACC 
and thalamus was negatively correlated with RT variability in all participants (r=-.541, p=.0007 
and r=-.477, p=.006).  
 
3.3 Association with clinical and cognitive measures 
 
In the control participants, activity in the right DLPFC (BA 9) was positively correlated with 
BHS scores (r=.688, p=0.014, Fig 1C). No other correlations with the BHS were statistically 
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significant. In addition, for all participants combined, activity in the thalamus was negatively 
correlated with DSHI (r= -.390, p=0.048) and with BHS scores at a trend level (r=-.386, p=.052).  
 
In the self-harm patient group, activity in the right DLPFC (BA 9) was positively correlated with 
ISST scores (r=.715, p=.024, see Fig 1D) and activity in the left PCC (BA 23) was negatively 
correlated with CDSS scores (r=-.687, p=.039). However, these associations were not found to 
be significant in the non-self-harm patient group. Finally, the severity of positive and negative 
symptoms was not associated with any brain activations found during scanning.    
 
Correlations were performed between activity in the regions of interest and neuropsychological 
data. Right dorsal PCC (BA 31) activity and verbal IQ scores were negatively correlated at a 
trend level in the control group (r=-.573, p=.09). Accordingly, the direction of association 
between BA 31 activity and cognitive performance was negative for all tests across groups. This 
is in line with the current findings showing that control participants exhibited deceased activation 
in this area compared with the patient groups. Finally, in all participants, right VLPFC activity 
(BA 47) was negatively correlated with Trails A (r=-.407, p=.033) and B (r=-398, p=.041), 
indicating that increased activity in this area was associated with better performance. The right 
dorsal PCC (BA 31) activity was negatively associated with IQ scores (significant for full IQ, r=-
539, p<.001, as well as verbal, r=-.546, p<.001 and performance scores, r=-.403, p<.05). On the 
RWKHUKDQG&37SHUIRUPDQFHG¶ZDVSRVLWLYHO\FRUUHODWHGZLWKactivations in the ventral ACC 
(BA 24, r=.420, p=.025) and thalamus (r= .401, p=.038).  
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4. Discussion 
 
The primary finding is that activations associated with response inhibition using the go/no-go 
paradigm varied between the groups, indicating brain regions associated with self-harm in people 
with schizophrenia. Activations in the right DLPFC and left ventral PCC were higher in the 
control group than in those schizophrenia patients with self-harm histories, which in turn were 
higher than in patients without histories of self-harm. This suggests that activity in these areas is 
important in the phenomenon of self-harm by schizophrenia patients. Further support for this is 
provided by two statistical observations. First, for the patients who had self-harmed, go/no-go 
related activity in the right DLPFC was significantly correlated with severity of suicidal ideation. 
Second, hopelessness (a significant predictor of self-harm) was positively correlated with right 
DLPFC activity. These findings suggest a role for the right DLPFC in suicide and other self-
harm behaviors.  
 
The right DLPFC (BA 9) has previously been identified as a brain area showing alterations in 
function both at rest and during cognitive task performance in patients with major depression 
(Fitzgerald et al. , 2006). In addition, studies have demonstrated antidepressant effects of 
inhibitory transcranial magnetic stimulation to the right DLPFC (Klein et al. , 1999). 
Furthermore, relatively increased rCBF in right BA 9 in depressed patients experiencing high 
levels of mental pain associated with suicidality has been reported (van Heeringen, Van den 
Abbeele, 2010). Although BA 9 is a relatively long and large area, the peak coordinates of right 
%$LQYDQ+HHULQJHQHWDO¶s study (13, 39, 30) were in close proximity to ours (16, 42, 31). 
Thus, brain imaging findings from depression and our findings converge on a role for BA 9 in 
self-harm. This has significant implications for future neuromodulation studies targeting suicidal 
thinking and self-harm behaviors in these clinical groups. It should also be noted that this right 
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DLPFC activity associated with suicidal thinking and hopelessness appears to be task 
independent, as WKLVVDPHDUHD¶VDFWLYLW\LQWKHJR-rest contrast showed a similar level of 
significant associations (See Figure 1 Legend). Perhaps, though maladaptive, maintaining 
suicidal thinking requires working memory functions of the DLPFC.  
 
In addition to the right DLPFC activiations, we also found that ventral posterior cingulate 
activation (BA 23) differentiated all three groups whereas dorsal posterior cingulate activation 
(BA 31) differentiated schizophrenia groups from controls. Furthermore, lower activity in the 
ventral PCC was associated with depression in the schizophrenia patients with self-harm. On the 
other hand, dorsal PCC activity was mainly related to cognitive performance; such that decreased 
activity in this area was associated with better cognitive performance. These findings are 
consistent with emerging evidence of anatomical and functional differences between the ventral 
and dorsal posterior cingulate. Leech and colleagues have suggested that the ventral PCC is more 
involved in internally directed attention and emotion along with its functional connectivity with 
the temporal lobes, whereas the dorsal PCC is actively involved in the control/switch of 
internally and externally focused attention and cognition in conjunction with the medial 
prefrontal cortex (Leech et al. , 2011) 
 
A further finding is that the schizophrenia patients, in comparison to the controls, consistently 
failed to activate the right VLPFC, left ventral ACC, and right thalamus. Hence, these are 
sensitive to schizophrenia diagnosis during scanning using the go/no-go task. Our findings are 
consistent with previous schizophrenia studies that have used the same equi-probable go/no-go 
task reporting decreased right VLPFC activity (Kaladjian et al. , 2007). While a more recent 
study by the same group IRXQGDSRVLWLYHFRUHODWLRQEHWZHHQVFRUHVRQ%DUUDWW¶VWUDLW
impulsiveness scale and activities in the right VLPFC in patients with schizophrenia during a 
go/no-go task (Kaladjian, Jeanningros, 2011), we did not find such an association. This 
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inconsistency may be attributable to low implusivity scores in our patient groups, as the healthy 
FRQWUROJURXS¶VLPSXOVLYLW\VFRUHVZHUHQRWVWDWLVWLFDOO\different.    
 
Considerable evidence suggests that ACC-thalamic system activity is associated with increased 
alertness and concentration (Paus, 2001). Compared with the control group, the schizophrenia 
patients exhibited decreased activation in the ventral ACC and thalamus. Previous studies 
utilizing various response inhibition tasks have also found that ACC and thalamic activation 
were reduced in patients with schizophrenia (Barkataki et al. , 2008, Rubia et al. , 2001). 
Furthermore, we found that ventral ACC activity was significantly negatively correlated with the 
number of omission errors and response variability during scanning and positively correlated 
with CPT performance. This suggests that alertness and concentration may be mediated by the 
activity in the ACC-thalamic system during the go/no-go task, and patients with schizophrenia 
fail to utilize this system during performance.  
 
However, it should be noted that overall task performance did not vary between the groups, 
despite numerous differences in neural processing revealed by fMRI. Such observations are 
common in functional imaging studies of psychiatric patients. In some cases, behavioral 
performance is worse despite normal brain activations. For example, a recent study using the 
go/no-go task with bipolar I patients found that despite poor task performance compared to 
controls, imaging data did not reveal any differences (Welander-Vatn et al. , 2013). In other 
studies, such as ours, activations are abnormal despite normal behavioral performance (Eyler et 
al. , 2004). These differences probably reflect abnormalities of neural processing by psychiatric 
patients that can manifest as either alterations to functional routes in the brain or less efficient 
processing. In the case of the current research, it is suggested that the task was performed by the 
schizophrenia patients with less reliance on the DLPFC, VLPFC and thalamus of the right 
hemisphere and cingulate regions of the left hemisphere, with compensatory strategies involving 
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the right dorsal PCC (BA 31), which was found to be more active in the patients compared to the 
controls in the no-go versus rest contrast.  
 
In addition to the neural activation findings, we observed that patients with a history of self-harm 
showed significantly higher levels of hopelessness when compared to those without a history of 
self-harm. Hopelessness has been linked to suicide among people with schizophrenia (Steblaj et 
al. , 1999). However, we noted previously with a larger sample (Pluck, Lekka, 2012), that neither 
severities of positive nor negative symptoms were linked to self-harm. A recent study of 509 
schizophrenia patients has also reported that positive and negative symptoms are not predictive 
of suicide attempts (Jovanovic et al. , 2013). Similarly, severity of positive and negative 
symptoms were not associated with any self-harm related brain activations in our study. These 
findings suggest that we should look beyond the core symptoms to improve prevention strategies 
for self-harm in patients with schizophrenia. This could include measures of impulsiveness or 
hopelessness, as well as the possibility of functional imaging to identify those patients at risk.  
 
There are some limitations to this study. First, our no-go versus go contrast did not show any 
significantly activated brain DUHDVLQDQ\JURXS7KLVZDVSDUWO\EHFDXVHµJR¶WULDOVDOVRDFWLYDWHG
inhibition-related brains areas including bilateral VLPFC, in addition to motor and sensory areas. 
This finding could LQGLFDWHWKDWUHVSRQVHVHOHFWLRQLQµJR¶WULDOVDQGUHVSRQVHLQKLbition 
(selecting not to respond in no-go trials) share the same neural circuitry (Mostofsky and 
Simmonds, 2008). Furthermore, the use of a simple, relatively non-demanding, go/no-go task in 
our study may have contributed to the non-significant finding, as cognitive demands for no-go 
trials would be lower compared with a working memory go/no-go task (Simmonds et al. , 2008). 
Nevertheless, the no-go versus rest contrast was sufficient for the purpose of comparing patients 
with a history of self-harm to those without a history of self-harm and to healthy controls.  
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Second, an intriguing finding in this study was that, although right DLPFC activation was not 
significant in the no-go versus rest contrast in any group, it was significantly different across 
groups from the ANOVA. This observation suggests that right DLPFC activity in our study may 
be task-independent, despite significant right DLPFC activations during response inhibition 
having commonly been reported (Nakata et al. , 2008). Indeed, we isolated activity in the same 
coordinates in the go versus rest contrast, and confirmed that we found significant correlations as 
in the no-go versus rest contrast. In order to test this idea further, studies should employ separate 
paradigms to confirm whether right DLPFC activity differences exist between patients with- and 
without the tendency to self -harm. Finally, our sample size was relatively small. Hence, other 
group differences may not have been detected between patients with- and without self-harm. For 
example, in a larger sample we previously found that patients with history of self-harm had 
higher impulsivity scores than patients without history of self-harm (Pluck, Lekka, 2012). In the 
present study, however we did not find such a difference.  
 
5. Conclusion 
 
In conclusion, patients with schizophrenia who have a history of self-harm were distinguishable 
from those without a history of self-harm and control participants by their neural activity in the 
right DLPFC and left ventral PCC. Furthermore, right DLPFC activation is significantly 
positively associated with suicidal thinking in patients with a history of self-harm. This area 
could be a target for future neuromodulation studies to treat suicidal thinking in patients with 
schizophrenia. This work is the first step towards an attempt to help predict self-harm and suicide 
in patients with schizophrenia by their neural responses.    
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Figure legend 
 
 
Fig 1. Right dorsolateral prefrontal cortex (BA 9; 16, 42, 31) shown in the main effect of group 
from a three-group ANOVA for the no-go versus rest contrast (A) and box-plot displaying 
central tendency and variability for the right DLPFC activation for the three groups (B). Right 
DLPFC activity was positively correlated with Beck hopelessness scale scores (BHS) in healthy 
controls (C) and with the severity of suicidal thinking in patients with history of self-harm (ISST 
total scores, D). Note that this right DLPFC activity associated with hopelessness and suicidal 
thinking appears to be task independent, because activity in the same area in the go-rest contrast 
showed a similar level of significant association with total BHS scores in healthy controls 
(r=.629, p=.049) and with ISST total scores in patients with history of self-harm (r=.689, p=.036). 
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Table 1. Demographic and clinical data 
Variable  1. Patients with SH (n=14) 2. Patients without SH (n=14) 3. Controls (n=17) Between group comparisons 
Sex (No. M/F) 12/2 11/3 14/3 NS 
Age (years) 43.6  ± 11.3 38.9 ± 7.3 37.9 ± 12.9  NS 
Premorbid IQ (NART) a 103.4 ± 11.6 102.5 ± 10.0 111.6 ± 7.9 3>1, p=.03; 3>2, p=.02  
Current IQ (WASI)  89.50 ±15.936 89.79 ± 17.197 107.47 ± 18.517 3>1, p=.005; 3>2, p=.005 
   WASI Verbal IQ 88.86 ± 21.328 90.14 ± 17.386 105.53 ± 18.822 3>1, p=.021; 3>2, p=.032 
   WASI Performance IQ 92.14 ± 15.372 91.50 ± 15.250  107.47 ± 13.375 3>1, p=.006; 3>2, p=.004 
SANS total  8.7 ± 4.6 7.7 ± 4.9  NS 
SAPS total  5.8 ± 3.2 4.4 ± 3.1  NS 
CPZ equivalent dose (mg/day) 466 ± 363 450 ± 288  NS 
Deliberate Self-harm (DSHI) 2.2 ± 2.0 0 0.29 ± .01 1 >2, p<.001; 1>3, p<.001 
Suicidal Ideation (ISST) 3.1 ± 4.9 0.3 ± 0.8  1>2, p=.06 
Impulsivity (BIS) 72.1 ± 6.8 68.9 ± 11.9 67.0 ± 9.2 NS 
Depression (CDRS) 5.1 ± 4.2 4.2 ± 2.0   NS 
Hopelessness (BHI) 9.0 ± 7.4 3.7 ± 1.9 3.0 ± 2.9 1 >2, p=.004; 1>3, p=.001 
Social functioning (LSP)  64.6 ± 12.7 61.4 ± 15.9  NS 
Illness Insight (SAI)  12.4 ± 4.2 13.4 ± 3.2  NS 
Substance Abuse (DSM-IV: 
Yes/No) 4/10 
 
2/12 0/17 
 
X2 =5.4, p=.06 
a Estimated from scores on the National Adult Reading Test (NART).  
Abbreviations: WASI, Wechsler Abbreviated Scale of Intelligence; CPZ, Chlorpromazine; SANS, Schedule for the Assessment of Negative 
Symptoms; SAPS, Schedule for the Assessment of Positive Symptoms; SAI, Schedule of Assessment of Insight; LSP, Life Skills Profile;  
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Table 2. Brain areas significantly activated during correct no-go versus rest trials in control group and patient groups  
Region (BA) Coordinate (x, y, z) Cluster size Z-value 
Healthy controls 
   
  
  Left ACC (32) -6 14 38 625 6.44 
Right ventrolateral prefrontal cortex       
(VLPFC) (47) 32 25 1 341 6.08 
  Left insular -36 10 -2 177 6.07 
  Right posterior cingulate (23) 6 -22 23 222 6.06 
  Right cerebellum 2 -63 -22 154 5.33 
  Left precentral gyrus (6) -46 -2 41 13 5.13 
  Right  inferior parietal lobule (40) 30 -45 37 11 5.03 
  Right thalamus 8 -17 16 5 4.79 
  Left thalamus -14 -10 0 7 4.76 
Patients with history of self-harm 
   
  
  Left ACC (32) -4 12 40 33 5.49 
  Right precuneus (7) 30 -47 39 24 5.26 
  Right medial frontal cortex (32) 10 12 47 86 5.18 
  Left fusiform gyrus (37) -42 -63 -9 23 5.04 
  Right ACC (32) 8 21 30 8 4.75 
Patients without history of self-harm 
   
  
  Right superior parietal lobule (7) 30 -49 39 168 6.61 
  Left precentral gyrus (6) -40 2 35 119 5.97 
  Left fusiform gyrus (19) -40 -65 -9 70 5.71 
  Right cerebellum 8 -71 -18 69 5.48 
  Right ACC (32) 8 18 41 175 5.45 
  Left precuneus (7) -26 -59 34 146 5.36 
  Left cerebellum -32 -52 -21 32 5.27 
  Left cerebellum -34 12 1 9 4.93 
  Left inferior parietal lobule (40) -40 -45 37 15 4.76 
  Right superior frontal gyrus (6) 8 8 53 7 4.74 
25 
 
 
 
Table 3. Significant regions exhibiting the main effect of group in the analysis of variance (1=Patients with SH, 2=Patients without SH, 3 
healthy control participants) 
 
Region (BA) Coordinate (x, y, 
z) 
Cluster 
size 
Z value Between group comparisons 
Right ventrolateral prefrontal cortex (VLPFC) 
(47) 
28, 30, -14 34 3.99 3 > 1, p<.001; 3> 2, p <.001 
Left ventral anterior cingulate (24) -14, 11, 31 14 3.88 3 > 1, p<.001; 3> 2, p <.001 
Right dorsal posterior cingulate (31) 6, -52, 47 8 3.73 1 > 3, p<.001; 2> 3, p <.001 
Right dorsolateral prefrontal cortex (9)  16, 42, 31 17 3.67 3 > 1, p=.021; 3> 2, p <.001; 1>2, 
p=.037 
Right thalamus 8, -19, 16 5 3.38 3 > 1, p<.001; 3> 2, p <.01 
Left ventral posterior cingulate (23) 2, -20, 27 8 3.21 3 > 1, p=.038; 3> 2, p <.001; 1>2, 
p=.05 
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Supplementary Table 1. Brain areas significantly activated during correct go versus rest trials in control group and patient groups 
 
Region (BA) Coordinate (x, y, z) Cluster size Z-value 
Healthy controls 
   
  
Left insula/ ventrolateral prefrontal cortex  
(VLPFC) (47) -36 10 0 577 7.00 
  Left medial globus pallidus/Thalamus -14 -12 -1 1524 6.91 
  Left anterior cingulate cortex (BA 24) -12 11 31 1135 6.88 
Right ventrolateral prefrontal cortex  
(VLPFC) (47) 32 25 1 569 6.83 
  Right cerebellum 2 -63 -22 698 6.67 
  Left post central gyrus (3) -40 -21 51 543 5.83 
  Left post central gyrus (40) -48 -33 48 37 5.72 
  Left cerebellum -24 -61 -24 51 5.09 
  Right parietal supramarginal gyrus (40) 40 -37 35 16 4.95 
  Right cerebellum 6 -28 -9 7 4.87 
  Left precuneus (7) -24 -56 36 28 4.83 
  Right inferior parietal lobule (40) 30 -45 37 7 4.71 
Patients with history of self-harm 
   
  
  Right cerebellum 2 -63 -24 1732 6.86 
  Right medial frontal cortex (32)  12 12 47 1640 6.57 
  Left post central gyrus (3) -44 -21 47 1639 6.52 
  Left substania nigra -8 -20 -9 1160 6.42 
  Right superior temporal gyrus (22) 50 10 0 411 6.17 
  Right globus pallidus 20 -10 2 371 6.05 
  Right precuneus (7) 30 -47 41 73 5.58 
  Right inferior parietal lobule (40) 42 -31 37 57 5.34 
  Left insula -48 -36 22 143 5.30 
  Right dorsolateral prefrontal cortex (9) 46 1 22 130 5.28 
Patients without history of self-harm  
   
  
  Right cerebellum -32 -52 -23 226 6.70 
  Right cerebellum 2 -69 -17 556 6.64 
28 
  Left inferior parietal lobule (40) -46 -31 42 2150 6.42 
  Left cerebellum -34 12 1 145 6.03 
  Right superior parietal lobule (7) 30 -49 39 197 5.95 
  Medial frontal cortex (32) 0 10 47 802 5.91 
  Right medial frontal cortex (6) 18 -1 53 29 5.83 
  Left fusiform gyrus (37) -40 -63 -9 64 5.70 
  Left post central gyrus (40) -51 -23 16 56 5.55 
Right ventrolateral prefrontal cortex        
(VLPFC) (47) 42 13 -4 111 5.43 
  Left cerebellum -6 -28 -7 13 5.06 
  Left anterior cingulate cortex (24) -10 -17 40 16 5.02 
  Left pre central gyrus (6) -22 -13 49 9 4.95 
  Right superior temporal gyrus (22) 53 10 3 6 4.90 
  Left anterior cingulate cortex (33) 4 11 23 22 4.88 
  Right posterior cingulate cortex (23) 10 -55 19 10 4.83 
  Right middle frontal gyrus (6) 28 -4 43 11 4.74 
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Supplementary Table 2. Brain areas significantly activated during correct go versus no-go trials in control group and patient groups  
 
Region (BA) Coordinate (x, y, z) Cluster size Z-value 
Healthy controls 
   
  
  Left postcentral gyrus (2) -50 -23 44 593 5.97 
  Right cerebellum 14 -47 -16 67 5.31 
  Left superior temporal gyrus (38) -40 -2 -8 79 5.27 
  Left postcentral gyrus (3) -38 -38 53 8 4.70 
Patients with history of self-harm 
   
  
  Left paracentral lobule (5) -16 -36 48 2582 7.28 
  Left cerebellum -22 -46 -20 1905 6.43 
  Right insula 42 -4 -1 675 6.37 
  Right medial frontal cortex (6) 6 -3 54 2108 6.33 
  Left superior temporal gyrus (38) -40 -1 -10 521 6.28 
  Right postcentral gyrus (2) 34 -29 42 340 5.81 
  Right middle frontal gyrus (6) 18 -11 56 29 5.51 
  Left cuneus (30) -2 -72 7 149 5.36 
  Left head of caudate 12 4 5 63 5.07 
  Left thalamus -12 -7 6 6 4.92 
  Right parahippocampal gyrus (30) 24 -54 3 13 4.79 
  Left thalamus -12 -19 3 18 4.66 
Patients without history of self-harm 
   
  
  Left postcentral gyrus (2) -50 -25 44 2021 6.62 
  Right superior frontal gyrus (6) 6 14 49 717 6.06 
  Left precuneus (7) -24 -52 52 90 5.70 
  Right precentral gyrus (44) 46 4 7 65 5.59 
  Right cerebellum 14 -47 -16 83 5.23 
  Left insula -38 0 0 35 5.12 
  Left putamen -32 -3 9 15 5.04 
  Right postcentral gyrus (2) 34 -29 42 13 4.93 
30 
  Right superior temporal gyrus (22) 53 10 3 8 4.88 
  Left cerebellum -28 -52 -24 20 4.83 
  Left inferior parietal lobule (40) -36 -52 49 6 4.68 
  Left paracentral lobule (5) -20 -34 51 13 4.68 
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